The aurora kinases in cell cycle and leukemia

B Goldenson, JD Crispino - Oncogene, 2015 - nature.com
The Aurora kinases, which include Aurora A (AURKA), Aurora B (AURKB) and Aurora C
(AURKC), are serine/threonine kinases required for the control of mitosis (AURKA and …

GATA factor mutations in hematologic disease

JD Crispino, MS Horwitz - Blood, The Journal of the American …, 2017 - ashpublications.org
GATA family proteins play essential roles in development of many cell types, including
hematopoietic, cardiac, and endodermal lineages. The first three factors, GATAs 1, 2, and 3 …

The landscape of somatic mutations in Down syndrome–related myeloid disorders

K Yoshida, T Toki, Y Okuno, R Kanezaki, Y Shiraishi… - Nature …, 2013 - nature.com
Transient abnormal myelopoiesis (TAM) is a myeloid proliferation resembling acute
megakaryoblastic leukemia (AMKL), mostly affecting perinatal infants with Down syndrome …

Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies

NL Michmerhuizen, JM Klco… - Blood, The Journal of …, 2020 - ashpublications.org
Abstract Nucleoporin 98 (NUP98) fusion oncoproteins are observed in a spectrum of
hematologic malignancies, particularly pediatric leukemias with poor patient outcomes …

[HTML][HTML] Differentiation therapy of myeloid leukemia: four decades of development

V Madan, HP Koeffler - Haematologica, 2021 - ncbi.nlm.nih.gov
Acute myeloid leukemia is characterized by arrested differentiation, and agents that
overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic …

[HTML][HTML] Targeted therapies for pediatric AML: gaps and perspective

A Lonetti, A Pession, R Masetti - Frontiers in pediatrics, 2019 - frontiersin.org
Acute myeloid leukemia (AML) is a hematopoietic disorder characterized by numerous
cytogenetic and molecular aberrations that accounts for~ 25% of childhood leukemia …

NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern

JDE de Rooij, IHIM Hollink, S Arentsen-Peters… - Leukemia, 2013 - nature.com
Cytogenetic abnormalities and early response to treatment are the main prognostic factors in
acute myeloid leukemia (AML). Recently, NUP98/NSD1 (t (5; 11)(q35; p15)), a …

CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype

R Masetti, M Pigazzi, M Togni, A Astolfi… - Blood, The Journal …, 2013 - ashpublications.org
Pediatric cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous
subgroup of myeloid clonal disorders that do not harbor known mutations. To investigate the …

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML …

JL Smith, RE Ries, T Hylkema, TA Alonzo… - Clinical Cancer …, 2020 - AACR
Abstract Purpose: A cryptic inv (16)(p13. 3q24. 3) encoding the CBFA2T3–GLIS2 fusion is
associated with poor outcome in infants with acute megakaryocytic leukemia. We aimed to …

Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study

JDE De Rooij, R Masetti… - Blood, The Journal …, 2016 - ashpublications.org
Genetic abnormalities and early treatment response are the main prognostic factors in acute
myeloid leukemia (AML). Acute megakaryoblastic leukemia (AMKL) is a rare subtype of …